NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Obese Adults, MDD

In brief

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

Key facts

Study ID

NCT07439744

Run by

National Science and Technology Council, Taiwan

People needed

50

Starts

2025-03-01

Expected to finish

2027-12-01

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older, up to 54. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Major depressive disorder.
• Antidepressant drug-free.

You may not qualify if…

• Schizophrenia
• Mania
• Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
• Obsessive-compulsive disorder
• Post-traumatic stress disorder
• Alcohol or drug abuse/dependence (except for nicotine)
• Active suicidal ideation
• Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement

Where it is running

• Mind Body Interface Research Center (MBI Lab & Care) — Taichung, Taichung, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.